10.79
+0.22(+2.08%)
Currency In USD
| Previous Close | 10.57 |
| Open | 10.53 |
| Day High | 10.99 |
| Day Low | 10.5 |
| 52-Week High | 14.44 |
| 52-Week Low | 4 |
| Volume | 800,367 |
| Average Volume | 925,001 |
| Market Cap | 921.16M |
| PE | -19.27 |
| EPS | -0.56 |
| Moving Average 50 Days | 8.62 |
| Moving Average 200 Days | 8.4 |
| Change | 0.22 |
If you invested $1000 in Anavex Life Sciences Corp. (AVXL) 10 years ago, it would be worth $5,187.5 as of July 06, 2025 at a share price of $10.79. Whereas If you bought $1000 worth of Anavex Life Sciences Corp. (AVXL) shares 5 years ago, it would be worth $2,320.43 as of July 06, 2025 at a share price of $10.79.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences
GlobeNewswire Inc.
May 14, 2025 11:30 AM GMT
H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and H.C. Wainwright 6th Annual Neuro Perspectives ConferenceNEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clin
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025
GlobeNewswire Inc.
May 06, 2025 11:30 AM GMT
Webcast and Conference Call To be Held Tuesday, May 13, 2025, 8:30 am ETNEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developi
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
GlobeNewswire Inc.
May 01, 2025 11:30 AM GMT
Study ANAVEX3-71-SZ-001 successfully completes enrollment with a total of 71 participants Both Part A (16 participants) and Part B (55 participants) of the placebo-controlled Phase 2 study fully enrolled Top line data expected in the second half of 2